The recent emergence of Coronavirus Disease in 2019 (COVID-19), caused by infection by SARS-CoV-2, has put the world on high alert. People are concerned about how soon drugs and vaccines will be available after the isolation of virus strains and the completion of sequencing and comparative analysis.
Read More ›
Cyagen Biosciences Suzhou Inc. closed a 285 million RMB (equivalent to about $41 million USD) Series B financing as of Feb 25. The investments are from funds managed by CMS Capital, GF Qianhe and GF Xinde which are both wholly owned by GF securities, and Guanghua Investment respectively.
Read More ›
An outbreak of COVID-19 (Coronavirus Disease in 2019) caused by the novel coronavirus, officially named SARS-CoV-2, swept across the world from Wuhan at the end of 2019 - having since brought a huge impact on the lives of people both in China and abroad.
Read More ›
Since the identification of the intermediate filament (IF), nestin, it has been used as a marker for Neural Stem Cells (NSCs) and commonly considered as a key component of the cytoskeleton.
Read More ›
Since the early 2000s, large-scale knockout consortia have been established with the goal of generating a complete resource of reporter-tagged null mutations in C57BL/6 mouse ES cells. Herein, we provide a brief introduction to the ‘knockout-first’
Read More ›
As CRISPR-based innovations begin to move into clinical testing and the dispute over core patents continues worldwide, CRISPR-Cas9 gene editing has been under increased scrutiny in both commercial and academic sectors.
Read More ›
Synaptic impairment is known to be a prerequisite to the cognitive deficiencies exhibited in Alzheimer's Disease (AD), so investigating the mechanisms which
Read More ›
Genetically engineered animals remain essential for gaining proper understanding of human disease mechanisms and play an important role in a variety of research areas.
Read More ›
We use cookies to ensure that we give you the best experience on our website. To learn about how we
keep your information safe, view our Privacy Policy.
OKPrivacy policy
